SGLT-2 inhibitors were associated with the lowest risk for incidental dementia relative to DPP-4 inhibitors and GLP-1RAs in type 2 diabetes.

The study will evaluate the safety, tolerability and pharmacokinetic characteristics of the company's exenatide implant.

The companies will deliver products for diabetes and weight control in specific nations across the Middle East.

Semaglutide was linked to a significantly lower risk of overdose than other antidiabetic drugs in patients with type 2 ...

According to health experts, if you eat the right foods, your body will trigger the natural release of GLP-1 – which is what ...

In 1970, with a degree from the medical school of the University of Copenhagen (UCPH), Professor Jens Juul Holst embarked on ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

An emerging market for compounded weight loss injections that mimic brand-name drugs such as Ozempic, Wegovy, Mounjaro and ...

We recently compiled a list of the 10 best performing Warren Buffett stocks in 2024. In this article, we are going to take a ...

For patients with type 2 diabetes (T2D) and opioid use disorder (OUD), semaglutide is associated with a significantly lower risk for opioid overdose compared with other antidiabetic medications.